Lexington Biosciences, Inc.

OTC: LXGTF · Healthcare · Medical - Specialties

Canadian filerHQ Vancouver, BCReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ —GM —SS 42

v0.1 · 5/100 weight · pillars only

↑ workforce scale, disclosure history · ↓ market scale, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$131.4k

Employees

543

Market cap

$379

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2023

Net income-$131.4k-177.4k CAD2023

Operating income-$117.1k-158.0k CAD2023

Total assets$00 CAD2023

Liabilities$747.6k988.8k CAD2023

Equity-$747.6k-988.8k CAD2023

Revenue trend

FY2017 – FY2023 · USD

FY17

FY18

FY19

FY20

FY21

FY22

FY23

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Lexington Biosciences, Inc. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Thoughtful Brands Inc.——Hear AtLast Holdings, Inc.——Ormand Industries Inc——InnerScope Hearing Technologies, Inc.——

Key facts

CEODonald Arthur McInnes

SectorHealthcare

IndustryMedical - Specialties

HeadquartersVancouver, BC

ExchangeOTC: LXGTF

Employees543

IPO date2017-07-19

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.